Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Account Payables (2020 - 2026)

Cytek Biosciences filings provide 6 years of Change in Account Payables readings, the most recent being -$1.3 million for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 607.36% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $448000.0, a 82.65% decrease, with the full-year FY2025 number at $448000.0, down 82.65% from a year prior.
  • Change in Account Payables hit -$1.3 million in Q4 2025 for Cytek Biosciences, down from $588000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.8 million in Q1 2022 to a low of -$2.0 million in Q2 2023.
  • Median Change in Account Payables over the past 5 years was $281500.0 (2023), compared with a mean of $142600.0.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 2383.93% in 2022 and later crashed 607.36% in 2025.
  • Cytek Biosciences' Change in Account Payables stood at -$742000.0 in 2021, then fell by 22.37% to -$908000.0 in 2022, then tumbled by 97.58% to -$1.8 million in 2023, then surged by 114.38% to $258000.0 in 2024, then crashed by 607.36% to -$1.3 million in 2025.
  • The last three reported values for Change in Account Payables were -$1.3 million (Q4 2025), $588000.0 (Q3 2025), and $759000.0 (Q2 2025) per Business Quant data.